Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer — Stella

Recruiting

Back to Ovarian Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

Key details

Phase

Safety & dosing

Sponsor

Sarah K. Lynam MD

Collaborators

Bayer

Enrollment target

~31 participants

Started

June 2022

Primary completion

September 2026

Age range

18 Years and older

Sex

Female only

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov